Davis Investment Partners LLC acquired a new stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 3,492 shares of the financial services provider's stock, valued at approximately $921,000.
Other hedge funds have also recently made changes to their positions in the company. Empowered Funds LLC raised its position in shares of CME Group by 28.4% in the fourth quarter. Empowered Funds LLC now owns 8,990 shares of the financial services provider's stock valued at $2,088,000 after purchasing an additional 1,987 shares during the period. Stephens Inc. AR boosted its stake in shares of CME Group by 6.4% in the 4th quarter. Stephens Inc. AR now owns 2,312 shares of the financial services provider's stock valued at $537,000 after purchasing an additional 140 shares in the last quarter. Kestra Private Wealth Services LLC boosted its position in CME Group by 34.0% during the 4th quarter. Kestra Private Wealth Services LLC now owns 4,738 shares of the financial services provider's stock valued at $1,100,000 after buying an additional 1,201 shares during the period. Summit Trail Advisors LLC raised its holdings in CME Group by 14.6% in the 4th quarter. Summit Trail Advisors LLC now owns 4,134 shares of the financial services provider's stock worth $986,000 after purchasing an additional 526 shares in the last quarter. Finally, Portfolio Design Labs LLC raised its holdings in CME Group by 50.0% in the 4th quarter. Portfolio Design Labs LLC now owns 13,987 shares of the financial services provider's stock worth $3,248,000 after purchasing an additional 4,661 shares in the last quarter. 87.75% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity at CME Group
In other news, Director Charles P. Carey sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $265.35, for a total transaction of $132,675.00. Following the transaction, the director now directly owns 4,900 shares of the company's stock, valued at approximately $1,300,215. This trade represents a 9.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Larry G. Gerdes sold 2,000 shares of CME Group stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $264.10, for a total value of $528,200.00. Following the completion of the transaction, the director now directly owns 38,651 shares of the company's stock, valued at $10,207,729.10. This represents a 4.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,400 shares of company stock worth $3,680,610. 0.30% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
Several analysts recently commented on CME shares. JPMorgan Chase & Co. cut their price objective on shares of CME Group from $223.00 to $211.00 and set an "underweight" rating on the stock in a research report on Thursday, April 24th. Oppenheimer boosted their price target on shares of CME Group from $282.00 to $300.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 4th. Erste Group Bank lowered shares of CME Group from a "strong-buy" rating to a "hold" rating in a research note on Saturday, May 24th. Raymond James raised shares of CME Group from a "market perform" rating to an "outperform" rating and set a $287.00 price objective for the company in a research note on Monday, March 10th. Finally, UBS Group increased their price target on shares of CME Group from $290.00 to $305.00 and gave the company a "buy" rating in a research report on Friday, April 25th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $258.20.
View Our Latest Stock Report on CME Group
CME Group Price Performance
CME stock traded up $1.31 during trading on Thursday, hitting $270.96. The company had a trading volume of 2,189,659 shares, compared to its average volume of 2,199,499. The company has a current ratio of 1.01, a quick ratio of 1.02 and a debt-to-equity ratio of 0.10. The business has a 50 day moving average of $272.07 and a 200 day moving average of $253.75. CME Group Inc. has a fifty-two week low of $190.70 and a fifty-two week high of $290.79. The firm has a market capitalization of $97.64 billion, a price-to-earnings ratio of 28.02, a P/E/G ratio of 6.76 and a beta of 0.45.
CME Group (NASDAQ:CME - Get Free Report) last released its earnings results on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.61 by $0.19. The company had revenue of $1.64 billion for the quarter, compared to analysts' expectations of $1.56 billion. CME Group had a return on equity of 13.62% and a net margin of 57.52%. The business's revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.50 EPS. As a group, research analysts predict that CME Group Inc. will post 10.49 earnings per share for the current year.
CME Group Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th will be issued a dividend of $1.25 per share. The ex-dividend date is Monday, June 9th. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.85%. CME Group's dividend payout ratio (DPR) is presently 50.30%.
CME Group Profile
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
See Also
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
